Skip to main content
SpringerLink
Log in

Prolactinomas in Men

  • Chapter
  • First Online:
Book cover Prolactin Disorders

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Prolactinomas in men have several peculiar features that distinguish them from female PRL-secreting tumors. They occur less frequently in the male gender but are usually larger, more frequently invasive, and more often aggressive than in women. Significantly higher prolactin concentrations are also observed in men as compared to women, especially in the case of macroprolactinoma. Sex differences in tumor behavior largely explain such characteristics, rather than the longer delay in making the diagnosis in men. The reasons for a more aggressive course of prolactinomas in men remain poorly understood, and some hypotheses will be discussed in this chapter.

Striking differences also exist in the clinical presentation of prolactinoma. Most women will present with oligomenorrhea, infertility, and/or galactorrhea, while more than half of men initially complain from symptoms of mass effects. Male hypogonadism is often present but neglected, and the male reproductive axis appears to be less sensitive to hyperprolactinemia than the female one. Nonetheless, diagnosis of prolactinoma in men should rely on the same criteria as in women, and a similar therapeutic strategy should be used. Medical management with dopamine agonists (DA) is effective and should always be considered as the first-line therapy, also in men bearing very large and compressive tumors. Transsphenoidal surgery is indicated in patients who are either intolerant or resistant to dopamine agonists or who elect to undergo potential curative surgery. However, most male patients with a macroprolactinoma will require medical treatment to control prolactin hypersecretion after surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol. 1994;41:359–64.

    Article  CAS  Google Scholar 

  2. Melmed S, Braunstein GD, Chang RJ, Becker DP. Pituitary tumours secreting growth hormone and prolactin. Ann Intern Med. 1986;105:238–53.

    Article  CAS  Google Scholar 

  3. Molitch ME. Pituitary tumours: pituitary incidentalomas. Best Pract Res Clin Endocrinol Metab. 2009;23:667–75.

    Article  CAS  Google Scholar 

  4. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485–534.

    Article  CAS  Google Scholar 

  5. Chanson P, Maiter D. Prolactinomas. In: Melmed S, editor. The pituitary. 4th ed: Academic Press/Elsevier, San Diego; 2017. p. 467–514.

    Chapter  Google Scholar 

  6. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769–75.

    Article  CAS  Google Scholar 

  7. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol. 2010;72:377–82.

    Article  Google Scholar 

  8. Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013;16:545–53.

    Article  Google Scholar 

  9. Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M, Benediktsson R. The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur J Endocrinol. 2015;173:655–64.

    Article  CAS  Google Scholar 

  10. Raappana A, Koivukangas J, Ebeling T, Pirila T. Incidence of pituitary adenomas in Northern Finland in 1992!2007. J Clin Endocrinol Metab. 2010;95:4268–75.

    Article  CAS  Google Scholar 

  11. Tjörnstrand A, Gunnarsson K, Evert M, Holmberg E, Ragnarsson O, Rosén T, Filipsson Nyström H. The incidence rate of pituitary adenomas in Western Sweden for the period 2001–2011. Eur J Endocrinol. 2014;171:519–26.

    Article  Google Scholar 

  12. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab. 2000;85:3053–7.

    CAS  PubMed  Google Scholar 

  13. Iglesias P, Bernal C, Villabona C, Castro JC, Arrieta F, Dıez JJ. Prolactinomas in men: multicentre and retrospective analysis of treatment outcome. Clin Endocrinol. 2012;77:281–7.

    Article  CAS  Google Scholar 

  14. Colao A. Pituitary tumors: the prolactinoma. Best Pract Res Clin Endocrinol Metab. 2009;23:575–96.

    Article  CAS  Google Scholar 

  15. Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 1996;81:2338–243.

    CAS  PubMed  Google Scholar 

  16. Khare S, Lila AR, Patt H, Yerawar C, Goroshi M, Bandgar T, Shah NS. Gender differences in macroprolactinomas: a single centre experience. Endocr Connect. 2016;5:20–7.

    Article  CAS  Google Scholar 

  17. Buurman H, Saeger W. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol. 2006;154:753–8.

    Article  CAS  Google Scholar 

  18. Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med. 1981;304:156–8.

    Article  CAS  Google Scholar 

  19. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997;82:2102–7.

    CAS  PubMed  Google Scholar 

  20. Colao A, Di Sarno A, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003;148:325–31.

    Article  CAS  Google Scholar 

  21. Paepegaey AC, Salenave S, Kamenicky P, Maione L, Brailly-Tabard S, Young J, Chanson P. Cabergoline tapering is almost always successful in patients with macroprolactinomas. J Endocr Soc. 2017;1:221–30.

    Article  CAS  Google Scholar 

  22. Nishioka H, Haraoka J, Akada K. Growth potential of prolactinomas in men: is it really different from women? Surg Neurol. 2003;59:386–90.

    Article  Google Scholar 

  23. Calle-Rodrigue RDP, Giannini C, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT, Stefaneanu L, Ebright AB, Abboud CF, Davis DH. Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc. 1998;73:1046–52.

    Article  CAS  Google Scholar 

  24. Schaller B. Gender-related differences in prolactinomas. A clinicopathological study. Neuro Endocrinol Lett. 2005;26:152–9. Erratum in Neuro Endocrinol Lett 2005; 26:628.

    PubMed  Google Scholar 

  25. Fainstein Day P, Glerean M, Lovazzano S, Pietrani M, Christiansen S, Balzaretti M, Kozak A, Carrizo A. Gender differences in macroprolactinomas: study of clinical features, outcome of patients and ki-67 expression in tumor tissue. Front Horm Res. 2010;38:50–8.

    Article  Google Scholar 

  26. Delgrange E, Vasiljevic A, Wierinckx A, François P, Jouanneau E, Raverot G, Trouillas J. Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol. 2015;172:791–801.

    Article  CAS  Google Scholar 

  27. Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009;160:747–52.

    Article  CAS  Google Scholar 

  28. Pont A, Shelton R, Odell WD, Wilson CB. Prolactin-secreting tumors in men: surgical cure. Ann Intern Med. 1979;91:211–3.

    Article  CAS  Google Scholar 

  29. Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E, François P, Galland F, Mougel F, Chapuis F, Villeneuve L, Maurage CA, Figarella-Branger D, Raverot G, Members of HYPOPRONOS. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013;126:123–35.

    Article  Google Scholar 

  30. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab. 1998;83:2777–80.

    Article  CAS  Google Scholar 

  31. Fideleff HL, Boquete HR, Suárez MG, Azaretzky M. Prolactinoma in children and adolescents. Horm Res. 2009;72:197–205.

    Article  CAS  Google Scholar 

  32. Salenave S, Ancelle D, Bahougne T, et al. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab. 2015;100:1177–786.

    Article  CAS  Google Scholar 

  33. Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014;170:R213–27.

    Article  CAS  Google Scholar 

  34. Shimon I, Sosa E, Mendoza V, Greenman Y, Tirosh A, Espinosa E, Popovic V, Glezer A, Bronstein MD, Mercado M. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary. 2016;19:429–36.

    Article  CAS  Google Scholar 

  35. Furtado SV, Saikiran NA, Ghosal N, Hegde AS. Giant, solid, invasive prolactinoma in a prepubescent boy with gynaecomastia. Pediatr Neurol. 2010;42:72–4.

    Article  Google Scholar 

  36. Krassas GE, Pontikides N, Kaltsas T. Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline. Horm Res. 1999;52:45–8.

    CAS  PubMed  Google Scholar 

  37. Delgrange E, Raverot G, Bex M, Burman P, Decoudier B, Devuyst F, Feldt-Rasmussen U, Andersen M, Maiter D. Giant prolactinomas in women. Eur J Endocrinol. 2013;170:31–8.

    Article  Google Scholar 

  38. Sarwar KN, Huda MS, Van de Velde V, Hopkins L, Luck S, Preston R, McGowan BM, Carroll PV, Powrie JK. The prevalence and natural history of pituitary hemorrhage in prolactinoma. J Clin Endocrinol Metab. 2013;98:2362–7.

    Article  CAS  Google Scholar 

  39. Faje A, Chunharojrith P, Nency J, Biller BM, Swearingen B, Klibanski A. Dopamine agonists can reduce cystic prolactinomas. J Clin Endocrinol Metab. 2016;101:3709–15.

    Article  CAS  Google Scholar 

  40. Eroukhmanoff J, Tejedor I, Potorac I, Cuny T, Bonneville JF, Dufour H, Weryha G, Beckers A, Touraine T, Brue T, Castinetti F. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. Eur J Endocrinol. 2017;176:323–8.

    Article  CAS  Google Scholar 

  41. Acharya SV, Gopal RA, Bandgar TR, Joshi SR, Menon PS, Shah NS. Clinical profile and long term follow up of children and adolescents with prolactinomas. Pituitary. 2009;12:186–9.

    Article  Google Scholar 

  42. Shimon I, Bronstein MD, Shapiro J, Tsvetov G, Benbassat C, Barkan A. Women with prolactinomas presented at the postmenopausal period. Endocrine. 2014;47:889–94.

    Article  CAS  Google Scholar 

  43. Santharam S, Tampourlou M, Arlt W, Ayuk J, Gittoes N, Toogood A, Webster R, Karavitaki N. Prolactinomas diagnosed in the postmenopausal period: clinical phenotype and outcomes. Clin Endocrinol. 2017;87:508–14.

    Article  CAS  Google Scholar 

  44. Gürlek A, Karavitaki N, Ansorge O, Wass JA. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol. 2007;156:143–53.

    Article  Google Scholar 

  45. Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005;239:27–36.

    Article  CAS  Google Scholar 

  46. Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172:R205–13.

    Article  CAS  Google Scholar 

  47. Gillam MP, Middler S, Freed DJ, Molitch ME. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab. 2002;87:4447–51.

    Article  CAS  Google Scholar 

  48. Hulting AL, Werner S, Hagenfeldt K. Oral contraceptive steroids do not promote the development or growth of prolactinomas. Contraception. 1983;27:69–73.

    Article  CAS  Google Scholar 

  49. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab. 2008;93:19–25.

    Article  CAS  Google Scholar 

  50. Radl DB. Apoptosis of lactotrophs induced by D2 receptor activation is estrogen dependent. Neuroendocrinology. 2008;88:43–52.

    Article  CAS  Google Scholar 

  51. Recouvreux MV, Lapyckyj L, Camilletti MA, Guida MC, Ornstein A, Rifkin DB, Becu-Villalobos D, Díaz-Torga G. Sex differences in the pituitary transforming growth factor-beta1 system: studies in a model of resistant prolactinomas. Endocrinology. 2013;154:4192–205.

    Article  CAS  Google Scholar 

  52. Faraoni EY, Camilletti MA, Abeledo-Machado A, Ratner LD, De Fino F, Huhtaniemi I, Rulli SB, Díaz-Torga G. Sex differences in the development of prolactinoma in mice overexpressing hCGβ: role of TGFβ1. J Endocrinol. 2017;232:535–46.

    Article  CAS  Google Scholar 

  53. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273–88.

    Article  CAS  Google Scholar 

  54. Green AI, Sherlock M, Stewart PM, Gittoes NJ, Toogood AA. Extensive experience in the management of macroprolactinomas. Clin Endocrinol. 2014;81:85–92.

    Article  CAS  Google Scholar 

  55. Carter JN, Tyson JE, Tolis G, Van Vliet S, Faiman C, Friesen HG. Prolactin-secreting tumors and hypogonadism in 22 men. N Engl J Med. 1978;299:847–52.

    Article  CAS  Google Scholar 

  56. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S, Lombardi G. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004;89:1704–11.

    Article  CAS  Google Scholar 

  57. De Rosa M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Di Sarno A, Lombardi G, Colao AM. The treatment with cabergoline for 24 months normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol. 2006;64:307–13.

    Article  Google Scholar 

  58. Leonard MP, Nickel CJ, Marales A. Hyperprolactinemia and impotence: why, when and how to investigate. J Urol. 1989;142:992–4.

    Article  CAS  Google Scholar 

  59. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008;93:4721–7.

    Article  CAS  Google Scholar 

  60. Shimon I, Benbassat C. Male prolactinomas presenting with normal testosterone levels. Pituitary. 2014;17(3):246–50.

    Article  CAS  Google Scholar 

  61. Sibal L, Ugwu P, Kendall-Taylor P, Ball SG, James RA, Pearce SH, Hall K, Quinton R. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary. 2002;5:243–6.

    Article  Google Scholar 

  62. Tirosh A, Benbassat C, Lifshitz A, Shimon I. Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary. 2015;18:108–15.

    Article  CAS  Google Scholar 

  63. George LD, Nicolau N, Scanlon MF, Davies JS. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas. Clin Endocrinol. 2000;53:595–9.

    Article  CAS  Google Scholar 

  64. Krogh J, Selmer C, Torp-Pedersen C, Gislason GH, Kistorp C. Hyperprolactinemia and the association with all-cause mortality and cardiovascular mortality. Horm Metab Res. 2017;49:411–7.

    Article  CAS  Google Scholar 

  65. Toulis KA, Robbins T, Reddy N, Balachandran K, Gokhale K, Wijesinghe H, Cheng KK, Karavitaki N, Wass J, Nirantharakumar K. Males with prolactinoma are at increased risk of incident cardiovascular disease. Clin Endocrinol. 2018;88:71–6.

    Article  CAS  Google Scholar 

  66. Karavitaki N, Thanabalasingham G, Shore HC, et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol. 2006;65:524–9.

    Article  CAS  Google Scholar 

  67. Kreutz J, Vroonen L, Cattin F, Petrossians P, Thiry A, Rostomyan L, Tshibanda L, Beckers A, Bonneville JF. Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference. Neuroradiology. 2015;57:679–84.

    Article  Google Scholar 

  68. Qu X, Wang M, Wang G, Han T, Mou C, Han L, Jiang M, Qu Y, Zhang M, Pang Q, Xu G. Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. Eur J Endocrinol. 2011;164:499–504.

    Article  CAS  Google Scholar 

  69. Sheplan Olsen LJ, Robles Irizarry L, Chao ST, Weil RJ, Hamrahian AH, Hatipoglu B, Suh JH. Radiotherapy for prolactin-secreting pituitary tumors. Pituitary. 2012;15:135–45.

    Article  Google Scholar 

  70. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518–22.

    Article  CAS  Google Scholar 

  71. Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B, Delemer B, Ciccarelli E, Beck-Peccoz P, Caron P, Daly AF, Beckers A. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012;167:651–62.

    Article  CAS  Google Scholar 

  72. Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, Elefante A, Cavallo LM, Briganti F, Cirillo S, Lombardi G. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol. 2007;67:426–33.

    Article  CAS  Google Scholar 

  73. Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. 2009;94:2428–36.

    Article  CAS  Google Scholar 

  74. Anagnostis P, Adamidou F, Polyzos SA, Efstathiadou Z, Karathanassi E, Kita M. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary. 2012;15:25–9.

    Article  Google Scholar 

  75. Teixeira M, Souteiro P, Carvalho D. Prolactinoma management: predictors of remission and recurrence after dopamine agonist withdrawal. Pituitary. 2017;20:464–70.

    Article  CAS  Google Scholar 

  76. Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab. 2002;87:3180–6.

    Article  CAS  Google Scholar 

  77. Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch, Buchfelder M. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol. 2008;158:11–8.

    Article  CAS  Google Scholar 

  78. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab. 2010;95:1708–16.

    Article  CAS  Google Scholar 

  79. Babey M, Sahli R, Vajtai I, et al. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary. 2011;14:222–30.

    Article  Google Scholar 

  80. Wolfsberger S, Czech T, Vierhapper H, Benavente R, Knosp E. Microprolactinomas in males treated by transsphenoidal surgery. Acta Neurochir. 2003;145:935–40.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc – Université catholique de Louvain, Brussels, Belgium

    Dominique Maiter

Authors
  1. Dominique Maiter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dominique Maiter .

Editor information

Editors and Affiliations

  1. Neuroendocrine and Pituitary Clinical Center, Massachusetts General Hospital, Boston, MA, USA

    Nicholas A. Tritos

  2. Neuroendocrine and Pituitary Clinical Center, Massachusetts General Hospital, Boston, MA, USA

    Anne Klibanski

Additional information

Disclosures: 

The author has no conflict of interest regarding this publication.

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Maiter, D. (2019). Prolactinomas in Men. In: Tritos, N., Klibanski, A. (eds) Prolactin Disorders. Contemporary Endocrinology. Humana, Cham. https://doi.org/10.1007/978-3-030-11836-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11836-5_11

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-11835-8

  • Online ISBN: 978-3-030-11836-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation